Ogiwara et al. showed that ARID1A-deficient cancer cells expressed low levels of the key cystine transporter SLC7A11 and thus exhibited low basal levels of GSH, which made these cancer cells specifically vulnerable to inhibition of the GSH metabolic pathway25. This evidence concerns the gene ARID1A and cancer.